Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2020

View Archived Issues

Glial metabolism affects neural recovery

Kemp Proteins to provide assay development for first-in-class chronic SCI therapy, AXER-204

Genentech and Roche divulge new antibacterials

Gilead Sciences presents new PKC agonists

First-in-human study of IGM-8444 begins in patients with solid tumors

AbbVie and Galapagos identify CFTR mutant correctors

New potential broad-spectrum fungicides discovered

Phase I data for sotorasib in advanced solid tumors harboring the KRAS p.G12C mutation

Researchers develop mouse-adapted SARS-CoV-2 model causing age-related disease pathogenesis

Cyteir Therapeutics describes RAD51A inhibitors

REVOLUTION Medicines patents SOS1 inhibitors

P2X4R inhibition reduces proinflammatory myeloid cells, offering neuroprotection after stroke

First clinical data presented for first-in-class NOTCH inhibitor CB-103

Henlius reports phase III data on bevacizumab biosimilar HLX-04

First-in-human study evaluates AZD-8701 alone and with durvalumab in advanced solid tumors

Debio-1143 studied in phase III with chemoradiotherapy for locally advanced SCCHN

M-8891 has manageable safety profile and favorable PK in first-in-human study

ILT4 antibody MK-4830 well tolerated, shows encouraging responses in phase I study

First-in-human data presented for TLD-1

Micreos begins phase I/IIa study of endolysin XZ.700 in atopic dermatitis

Durect eyes initiation of phase IIb trial of DUR-928 in alcoholic hepatitis

Vaccinex reports topline phase II data on pepinemab in Huntington's disease

FDA accepts IND for adoptive T-cell therapy GEN-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...